US EditionStudy: 82% Regain Weight After Stopping Mounjaro
Stopping tirzepatide led 82% of participants to regain at least 25% of lost weight and reversed improvements in blood pressure, cholesterol, and blood sugar, researchers found.
- Next year, a post-hoc analysis led by Deborah B. Horn found stopping tirzepatide was linked to reversal of cardiometabolic improvements with increases by week 88 in blood pressure, lipids, HbA1c, insulin, and waist circumference.
- Researchers warned continuous treatment may be needed, as long-term anti-obesity treatment may sustain weight and cardiometabolic benefits, but Deborah B. Horn, DO, MPH, and co-authors noted longer follow-up is necessary.
- By degree of regain, metabolic markers rose in step with weight return, with systolic blood pressure increasing 6.8 mm Hg to 10.4 mm Hg and fasting insulin rising up to 46.2% across regain categories.
- Clinicians should warn patients they will likely regain much weight and lose cardiometabolic benefits if they stop medication, and consider calling them chronic "weight management" drugs, Elizabeth Oczypok, MD, PhD, and Timothy S. Anderson, MD, MAS advised.
- The trial enrolled 308 adults with obesity or overweight meeting BMI criteria, nearly all on a 15-mg maximum tolerated tirzepatide dose, and maintaining a 500 calorie daily deficit plus at least 150 minutes/week activity.
18 Articles
18 Articles
Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity
About The Study: In this post hoc analysis of the SURMOUNT-4 trial, among participants with obesity who achieved weight reduction with 36-week tirzepatide (a glucagon-like peptide-1 receptor agonist) treatment, withdrawing tirzepatide led to 25% or greater weight regain in most participants within 1 year and was associated with a greater reversal of their initial cardiometabolic parameter improvements compared with those who maintained weig…
1 in 8 Americans have already tried Ozempic and similar weight loss medications
GLP-1 drugs like Ozempic have transformed weight loss in the U.S., with nearly 12% of Americans having tried them, according to a new RAND report. Usage is especially high among women aged 50 to 64, while men catch up in older groups. Despite effectiveness, side effects like nausea and diarrhea are common, and most Americans say they don’t plan to take them.
Three key benefits reversed within months after patients discontinue Mounjaro, scientists warn
People who stop taking the weight-loss medication Mounjaro don't just pile the pounds back on - they also lose the cardiovascular benefits that came with shedding weight, new research has warned
Cardiometabolic Gains Backslide After Halting Obesity Meds
(MedPage Today) -- Weight regain after the withdrawal of tirzepatide (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Among 308 participants with obesity...
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
